MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA

Zhan,Shijuan; Wang,Chunfeng; Yin,Fangqing

doi:10.3892/mmr.2018.8678

MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA

Authors:
- Shijuan Zhan
- Chunfeng Wang
- Fangqing Yin
View Affiliations

Affiliations: Department of Oncology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Medicine, Health School of Linyi, Linyi, Shandong 276000, P.R. China, Department of Pediatric Surgery, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China
Published online on: March 5, 2018 https://doi.org/10.3892/mmr.2018.8678
Pages: 6705-6710

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) is a primary sub-type of lung cancer with a high incidence rate and poor prognosis. The primary therapeutic treatment for NSCLC is chemotherapy, which is considered to be ineffective and excessively toxic. Novel therapeutic methods, particularly molecular targeted therapy, have attracted considerable attention. MicroRNAs (miRs) are reported to be potential biomarkers and targeted agents with roles in various types of tumors. Herein, the present study presented the observation of aberrant low expression of miR‑29c and associated overexpression of vascular endothelial growth factor A (VEGFA) in NSCLC tumor tissues. The effects of miR‑29c upon NSCLC tumor progression, including cell proliferation and cellular apoptosis, were investigated. The possible regulatory mechanism of action of miR‑29c on its direct target VEGFA and the phosphatidylinositol 3‑kinase (PI3K)/RAC‑α serine/threonine‑protein kinase (Akt) signaling pathway was examined using multiple methods, including reverse transcription-quantitative polymerase chain reaction analysis, dual luciferase assay and western blot analysis. The results demonstrated that miR‑29c expression was downregulated in NSCLC tumor tissues compared with normal tissues. A marked negative correlation in the expression of miR‑29c and VEGFA was observed in clinical NSCLC tissues and cultured NSCLC cells. Overexpression of miR‑29c may inhibit cell proliferation and accelerate the cellular apoptosis rate of NSCLC tumor cells. Furthermore, the overexpression of miR‑29c was demonstrated to be able to downregulate the expression levels of VEGFA and PI3K/Akt signaling pathway‑associated proteins. The results of the present study suggested that miR‑29c might regulate NSCLC tumor progression by targeting VEGFA.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay JJ, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C and Shen H: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
3	Peters S, Adjei AA, Gridelli C, Reck M, Kerr K and Felip E: ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23 Suppl 7:vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
4	Giovannetti E, Toffalorio F, De Pas T and Peters GJ: Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: A changing landscape? Pharmacogenomics. 13:1073–1086. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
6	Osada H and Takahashi T: MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 28:2–12. 2007. View Article : Google Scholar : PubMed/NCBI
7	Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 104:pp. 15805–15810. 2007; View Article : Google Scholar : PubMed/NCBI
8	Zhang HW, Wang EW, Li LX, Yi SH, Li LC, Xu FL, Wang DL, Wu YZ and Nian WQ: A regulatory loop involving miR-29c and Sp1 elevates the TGF-β1 mediated epithelial-to-mesenchymal transition in lung cancer. Oncotarget. 7:85905–85916. 2016.PubMed/NCBI
9	Gu A, Lu J, Wang W, Shi C, Han B and Yao M: Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer. Int J Biochem Cell Biol. 70:118–125. 2016. View Article : Google Scholar : PubMed/NCBI
10	Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Liu X, Zhang J, Li L and Liu C: The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer. Oncol Lett. 4:763–766. 2012. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Chuang JC, Neal JW, Niu XM and Wakelee HA: Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Lung Cancer. 90:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
14	NSCLC Meta-analyses Collaborative Group1, . Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet. 375:1267–1277. 2010. View Article : Google Scholar : PubMed/NCBI
15	Thomas A, Liu SV, Subramaniam DS and Giaccone G: Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 12:511–526. 2015. View Article : Google Scholar : PubMed/NCBI
16	Tibaldi C, D'Incecco A and Lagana A: MicroRNAs and targeted therapies in non-small cell lung cancer: Minireview. Anticancer Agents Med Chem. 15:694–700. 2015. View Article : Google Scholar : PubMed/NCBI
17	Van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA and Olson EN: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 105:pp. 13027–13032. 2008; View Article : Google Scholar : PubMed/NCBI
18	Qiu F, Sun R, Deng N, Guo T, Cao Y, Yu Y, Wang X, Zou B, Zhang S, Jing T, et al: miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. PLoS One. 10:e01209692015. View Article : Google Scholar : PubMed/NCBI
19	Lei X, Lei L, Zhang Z, Zhang Z and Cheng Y: Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease. Int J Clin Exp Pathol. 8:1565–1574. 2015.PubMed/NCBI
20	Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, Liu X, Zhang Y and Le H: Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One. 9:e877802014. View Article : Google Scholar : PubMed/NCBI
21	Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, Zhang H, Chen X, Yang Y and Liu G: miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). PLoS One. 8:e701922013. View Article : Google Scholar : PubMed/NCBI
22	Goos JA, de Cuba EM, Coupé VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JA, Menke-Van der Houven van Oordt CW, Geldof AA, Meijer GA, et al: Glucose transporter 1 (SLC2A1) and vascular endothelial growth factor a (VEGFA) predict survival after resection of colorectal cancer liver metastasis. Ann Surg. 263:138–145. 2016.PubMed/NCBI
23	Mao D, Zhang Y, Lu H and Zhang H: Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment. Tumor Biol. 35:8217–8223. 2014. View Article : Google Scholar
24	Geng L, Chaudhuri A, Talmon G, Wisecarver JL and Wang J: TGF-beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis. PLoS One. 8:e599182013. View Article : Google Scholar : PubMed/NCBI
25	Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI